ClinicalTrials.gg
WithdrawnNCT02092142Updated Jan 2, 2020

Safety and Immunogenicity of Q Fever Vaccine

A Phase 2 interventional study of Q fever Vaccine in Q Fever, sponsored by U.S. Army Medical Research and Development Command. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-02.

Sponsored by U.S. Army Medical Research and Development Command · Phase 2, Interventional, and Prevention

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 and collect data on incidence of occupational Q fever infection in vaccinated personnel.

02

Conditions studied

  • Q Fever

Keywords

  • Q fever
  • Coxiella burnetii
03

In context

Lead sponsor

U.S. Army Medical Research and Development Command is the lead sponsor of 153 studies on the registry; 8 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 16 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old.
  • Females of childbearing potential must agree to have a urine pregnancy test on the same day before receipt of skin test AND vaccine. (Exception: documented hysterectomy or ≥ 3 years of menopause.) The results must be negative. Females must agree to not become pregnant for 3 months after receipt of the skin test or vaccination.
  • Considered at risk for exposure to C burnetii and who have submitted a Request for Investigational New Drug (IND) Vaccines for the Q Fever vaccine.
  • Sign and date the approved informed consent document and Health Insurance Portability and Accountability Act (HIPAA) Authorization.
  • Have on their charts:

    • Up-to-date medical history (including concomitant medications)
    • Physical examination and laboratory tests within 1 year
    • Previous chest x-ray and electrocardiogram
  • Be medically cleared for participation by an investigator. Examinations or tests may be repeated at the discretion of the enrolling physician.
  • Willing to return for all follow-up visits.
  • Agree to report any adverse events (AEs) that may or may not be associated with administration of the test article for at least 28 days after vaccination and agree to report all serious adverse events (for example, resulting in hospitalization) for the duration of the subject's participation in the study (6 months).
  • Agree to defer blood, bone marrow, and organ donation for 1 year after receipt of skin test antigen and/or vaccine.

Exclusion criteria

Exclusion Criteria:

  • Prior history of Q fever disease or vaccination.
  • Clinically significant abnormal lab results (including evidence of hepatitis C, hepatitis B carrier state) or elevated liver function tests (two times the normal range or at the discretion of the principal investigator).
  • Personal history of an immunodeficiency or current treatment with an oral or intravenous immunosuppressive medication.
  • Confirmed HIV infection.
  • Heart valve disease: prosthetic heart valve or clinically significant heart murmur. (If a murmur is detected on examination, an echocardiogram may be obtained or subject may be referred to a cardiologist to determine clinical significance.)
  • Aneurysm/vascular graft.
  • Joint prosthesis.
  • History of chronic fatigue syndrome (or positive by chronic fatigue syndrome (CFS) Questionnaire criteria).
  • Positive pregnancy test or breast-feeding female.
  • Any known allergies to components of the vaccine:

    • Formalin
    • Eggs or chicken products
  • Administration of another vaccine or investigational product within 28 days of skin test and subsequent Q fever vaccination.
  • Any unresolved AE resulting from a previous immunization.
  • Transplant recipients, subjects with cancer, and those with chronic kidney disease.
  • A medical condition that, in the judgment of the principal investigator, would impact subject safety.
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Vaccinated

    The vaccine will be administered subcutaneously in the upper outer aspect of the arm (triceps area) with 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 (which equals 30 μg)

    Biological: Q fever Vaccine

Interventions

  • BiologicalQ fever Vaccine

    Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105

    Also known as: Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105

06

What researchers measure

Primary outcomes

  1. Change in Immunogenicity

    Immune response will be evaluated for per protocol subjects to determine the percentage of subjects who experience a ≥ fourfold rise in immunofluorescence assay (IFA) antibody titer after vaccination. Immunoglobulin M (IgM) at Day 28 or Day 56, or immunoglobulin G (IgG) at 6 months.

    Time frame: Day 28, Day 56, or 6 months

  2. Percentage of subjects with symptoms following Q fever vaccination

    Time frame: 6 months

  3. Percentage of subjects with erythema following Q fever vaccination along with severity and association with vaccination

    Time frame: 6 months

  4. Percentage of subjects with induration following Q fever vaccination along with severity and association with vaccination

    Time frame: 6 months

  5. Percentage of subjects with each AE, system organ class of AE, severity, and association with vaccination

    Time frame: 6 months

  6. Percentage of subjects with symptoms following Q fever skin test antigen

    Time frame: 6 months

  7. Percentage of subjects with erythema following Q fever skin test antigen along with severity and association with skin test antigen

    Time frame: 6 months

  8. Percentage of subjects with induration following Q fever skin test antigen along with severity and association with skin test antigen

    Time frame: 6 months

  9. Percentage of subjects with each AE, system organ class of AE, severity, and association with skin test antigen

    Time frame: 6 months

07

Study locations

1 site
  • Special Immunizations Program, Division of Medicine, USAMRIID
    Fort Deterick, Maryland 21702, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Feb 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2014
First posted
Mar 20, 2014
Start
Feb 2006
Primary completionEst.
Feb 2019
CompletionEst.
Dec 2019
Last update
Jan 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02092142
Collaborators
US Army Medical Research Institute of Infectious Diseases
Responsible party
Sponsor
First posted
Mar 20, 2014
Start date
Feb 2006
Primary completion
Feb 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Jan 2, 2020

Study contacts

Mark J Goldberg, MD
principal investigator · Special Immunizations Program, USAMRIID

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion